Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOD001 plus standard of care versus placebo plus standard of care in AL amyloidosis
2014-003865-11Phase 3Terminated
- Sponsor
- Prothena Corporation
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing NEOD001 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Time to all-cause mortality or cardiac hospitalization. Started May 2015; status: terminated.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2014-003865-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003865-11.